NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PTHS

Pelthos Therapeutics Inc

Jul 08 • 10:36AM ET

19.89

Dollar change -6.06
Percentage change -23.35	%

Healthcare • Biotechnology • USA • AMEX

Peers: VRTX BMRN SRPT BLUE ALNY IONS NBIX AMGN GILD REGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-17.31	Insider Own	0.00%	Shs Outstand	0.58M	Perf Week	57.86%
Market Cap	12.93M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	85.02%
Enterprise Value	13.97M	PEG	-	EPS next Q	-	Inst Own	9.89%	Short Float	-	Perf Quarter	45.84%
Income	-10.07M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.07	Perf Half Y	174.96%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-931.05%	Short Interest	0.01M	Perf YTD	210.30%
Book/sh	-2.45	P/C	10.34	EPS next 5Y	-	ROE	-	52W High	54.29 -63.36%	Perf Year	59.12%
Cash/sh	1.92	P/FCF	-	EPS past 3/5Y	-122.15% -	ROIC	-	52W Low	4.50 342.00%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	65.28% 25.34%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-144.61%	Oper. Margin	-	ATR (14)	4.79	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.39	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	63.59	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.39	EPS Q/Q	-18.68%	SMA20	43.39%	Beta	3.24	Target Price	85.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	64.83%	Rel Volume	4.32	Prev Close	25.95
Employees	-	LT Debt/Eq	-	Earnings	-	SMA200	68.70%	Avg Volume	106.26K	Price	19.89
IPO	Feb 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	96,781	Change	-23.35%

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malamut Richard	Director	Sep 12 '24	Buy	0.94	10,400	9,825	91,565	Sep 16 04:56 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 13 '24	Buy	0.97	3,500	3,395	547,710	Sep 16 04:55 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 12 '24	Buy	0.97	1,700	1,649	544,210	Sep 16 04:55 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 10 '24	Buy	0.89	6,500	5,785	537,010	Sep 12 05:35 PM
Francis Knuettel II	CEO, Pres., CFO, Treas & Secty	Sep 11 '24	Buy	0.94	5,500	5,170	542,510	Sep 12 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTHS

Pelthos Therapeutics Inc

Upgrade your FINVIZ experience